Login / Signup

Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.

Cara A RosenbaumUmut ÖzbekLarysa SanchezJonathan LagdameoAlex AbrahamsHani HassounOscar LahoudRuben NiesvizkyHeather J LandauKeren Osman
Published in: Blood advances (2022)
Keyphrases
  • newly diagnosed
  • high dose
  • low dose
  • open label
  • multiple myeloma
  • placebo controlled
  • double blind
  • clinical trial